XNYS · Health Information Services
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$260.21-1.34%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
63/100
Positive
Score components
TickerWhale View
Veeva Systems Inc - scores 63 out of 100 overall, which we rate positive. Risk is its strongest area and Valuation its weakest.
What helps
- Technical
- Quality & growth
- Risk
What to watch
- Valuation
Quality & growth
30%77Strong
- Revenue growth 16.5%
- EPS growth 25.7%
Valuation
25%23Weak
- P/E 42.3
- EV/Sales 11.9
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
#275 by market cap in our coverage · ~7,928 employees · Listed 2013-10-16 · www.veeva.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#37 / 139sector rank by TickerWhale Score
TickerWhale Score 63 vs sector average 55.1 (+7.9)
Revenue growth (industry)Top 44%
Gross margin (industry)Top 36%
Return on equity (industry)Top 55%
P/E (industry)Pricier than 75%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
79/100Strong vs universe
Ranks 79th of 100 covered names on our technical composite — the composite itself scores 63/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
4 buy · 2 sell · 2 neutral of 8 votes
TickerWhale rates VEEV's technical setup strong — 79th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
6 / 9constructive
- vs 200-day+30.6%
- vs 50-day+11.1%
Momentum
Mixed
- RSI (14)54 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rbuy
Trend
Mixed
- ADX (14) trend strength46· trending
- MACD (12,26,9)sell(histogram -3.473)
How the classic verdict is reached
Moving averages (9) agree on buy — 6 buy vs 3 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 2 sell · 2 neutral.
Result — 4 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)42.3
- P/S (TTM)12.4
- P/B5.8
- EV/EBITDA—
- EV/Sales11.9
- PEG1.65
Profitability & returns
- Gross margin75.0%
- Net margin29.3%
- ROE13.8%
- Debt/Equity0.00
Growth
- Revenue growth (YoY)16.5%
- EPS growth (YoY)25.7%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $42.9B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VEEVCurrentVeeva Systems Inc - | 63 | 63 | 42.3 | — | 5.8 | 11.9 | $260.21 | -1.34% | +16.5% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.